

| Computation of Retail Price based on Dec., 2015 Data under Para 4 of DPCO 2013 | | | | | | | | | | | | | | | |
|---|-------------------------|---------------------------------|-------------------|--------------------------------------|----------|-----------|------|-----------|-------------|--|---|-------------------------------------|-------------------------|------------------------------------|------|
| Diclofenac Gel 1% of M/s Blue Cross Labs Pvt. Ltd./M/s The Madras Pharmaceuticals | | | | | | | | | | Number of Companies consisting of Market Share of 1% & Above | | | | 11 | |
| | | | | | | | | | | Sum of MAT value considered for price calculation (in Lakhs) | | | | 20954.43 | |
| | | | | | | | | | | Sum of PTR per unit considered for price calculation | | | | 56.76 | |
| | | | | | | | | | | Number of Packs considered | | | | 27 | |
| | | | | | | | | | | Average PTR | | | | 2.10 | |
| | | | | | | | | | | Add : 16% Retailer Margin | | | | 0.34 | |
| | | | | | | | | | | Retail Price (without local taxes) | | | | 2.44 | |
| | | | | | | | | | | % Reduction with compared to Highest Price | | | | 21.64% | |
| | | | | | | | | | | Minimum Price (Rs.) | | | | 1.41 | |
| | | | | | | | | | | Maximum Price (Rs.) | | | | 2.68 | |
| | | | | | | | | | | Average of all considered (Rs.) | | | | 2.10 | |
| | | | | | | | | | | Retail Price (Rs.) | | | | 2.44 | |
| | | | | | | | | | | TOTAL MAT | | | | 2,174,844,340 | 100% |
| S. No. | Composition as per NLEM | पैक विवरण Pack Description | छाप BRAND | कंपनी Company | Strength | Pack Size | Unit | PTR (Rs.) | MAT (Rs.) | SKU wise MAT % | Company Levelwise MAT (ignoring 0% MAT) | Qualify (Y/N) (Y=Yes N=No) | Price per Unit (Rs.) | Price per Unit (Rs.) Considered | |
| 1 | DICLOFENAC M2A2 | ESGIPYRIN INSTA 1 % GEL 30 GM | ESGIPYRIN | ABBOTT HEALTHCARE PVT. LTD | 1 % | 30 | GM | 63.52 | 14,478,939 | 0.67% | 1.06% | Y | 2.12 | 2.12 | |
| 2 | DICLOFENAC M2A2 | TOPACFAST 1 % GEL 20 GM | TOPACFAST | ABBOTT HEALTHCARE PVT. LTD | 1 % | 20 | GM | 29.33 | 8,512,861 | 0.39% | 1.06% | Y | 1.47 | 1.47 | |
| 3 | DICLOFENAC M2A2 | DOLENTIA GEL 1 % GEL 30 GM | DOLENTIA GEL | AKUMENTIS HEALTHCARE LTD | 1 % | 30 | GM | 49.52 | 7,853,723 | 0.36% | 0.36% | N | 1.65 | | |
| 4 | DICLOFENAC M2A2 | ANAFAM 30 GM GEL | ANAFAM GEL | ALBERT DAVID LTD. | 1 % | 20 | GM | 51.57 | 16,261,186 | 0.75% | 0.75% | N | 2.58 | | |
| 5 | DICLOFENAC M2A2 | ENZOFAM MICRO 1 % GEL 30 GM | ENZOFAM | ALKEM LABORATORIES LTD. | 1 % | 30 | GM | 73.12 | 892,649 | 0.04% | 0.04% | N | 2.44 | | |
| 6 | DICLOFENAC M2A2 | DICLODYNE 1 % GEL 30 GM | DICLODYNE | BLISS CHEMICAL & PHARMACEUTICALS LTD | 1 % | 30 | GM | 48.51 | 618,551 | 0.03% | 0.03% | N | 1.62 | | |
| 7 | DICLOFENAC M2A2 | DICLOTAL 1 % GEL 30 GM | DICLOTAL | BLUE CROSS LABORATORIES LTD | 1 % | 30 | GM | 51.81 | 179,555 | 0.01% | 0.01% | N | 1.73 | | |
| 8 | DICLOFENAC M2A2 | DD (DALES) 1 % GEL 30 GM | DD (DALES) | DALES PHARMACEUTICALS LTD | 1 % | 30 | GM | 45.71 | 895,367 | 0.04% | 0.04% | N | 1.52 | | |
| 9 | DICLOFENAC M2A2 | NEXONAC 1 % GEL 30 GM | NEXONAC | EMENOX HEALTHCARE PVT LTD | 1 % | 30 | GM | 60.95 | 579,878 | 0.03% | 0.03% | N | 2.03 | | |
| 10 | DICLOFENAC M2A2 | ALOCK 1 % GEL 30 GM | ALOCK | GODDRES PHARMACEUTICALS LTD | 1 % | 30 | GM | 60.95 | 2,773,225 | 0.13% | 0.13% | N | 2.03 | | |
| 11 | DICLOFENAC M2A2 | PAINOXOL 1 % GEL 30 GM | PAINOXOL | GRAF LABORATORIES PVT LTD | 1 % | 30 | GM | 41.14 | 140,220 | 0.01% | 0.01% | N | 1.37 | | |
| 12 | DICLOFENAC M2A2 | XEROFLAM ULTRA 1 % GEL 30 GM | XEROFLAM ULTRA | HELIOS PHARMACEUTICALS | 1 % | 30 | GM | 68.57 | 4,807,374 | 0.22% | 0.22% | N | 2.29 | | |
| 13 | DICLOFENAC M2A2 | JUSGO 30 GM GEL | JUSGO GEL | INDI PHARMA PVT. LTD. | 1 % | 30 | GM | 61.54 | 25,000,000 | 1.15% | 1.15% | Y | 2.05 | 2.05 | |
| 14 | DICLOFENAC M2A2 | 3D 1 % GEL 30 GM | 3D | INTAS PHARMACEUTICALS LTD | 1 % | 30 | GM | 7.25 | 1,127,332 | 0.05% | 0.05% | N | 0.24 | | |
| 15 | DICLOFENAC M2A2 | DICLORAN 10 MG GEL 20 GM | DICLORAN | JB CHEMICALS | 1 % | 20 | GM | 79.18 | 382,870 | 0.02% | 0.02% | N | 3.96 | | |
| 16 | DICLOFENAC M2A2 | POWERGESIC PLUS 1 % GEL 30 GM | POWERGESIC PLUS | JENBURKT PHARMACEUTICALS LTD | 1 % | 30 | GM | 69.33 | 51,318,026 | 2.36% | 2.36% | Y | 2.31 | 2.31 | |
| 17 | DICLOFENAC M2A2 | ADIFLAM 1 % GEL 30 GM | ADIFLAM | LEBEN LABORATORIES PVT.LTD | 1 % | 30 | GM | 26.08 | 2,883,301 | 0.13% | 0.13% | N | 0.87 | | |
| 18 | DICLOFENAC M2A2 | VIVIAN 30 GM GEL | VIVIAN GEL | LINCOLN PHARMACEUTICALS LTD. | 1 % | 30 | GM | 48.62 | 14,064,984 | 0.65% | 0.65% | N | 1.62 | | |
| 19 | DICLOFENAC M2A2 | DICLONAC 1 % GEL 30 GM | DICLONAC | LUPIN LTD | 1 % | 30 | GM | 72.32 | 1,802,438 | 0.08% | 0.44% | N | 2.41 | | |
| 20 | DICLOFENAC M2A2 | DICLONAC TRANSGEL 1 % GEL 30 GM | DICLONAC TRANSGEL | LUPIN LTD | 1 % | 30 | GM | 72.32 | 7,872,596 | 0.36% | 0.44% | N | 2.41 | | |
| 21 | DICLOFENAC M2A2 | VOZOX 1 % GEL 30 GM | VOZOX | MACMILLON PHARMACEUTICALS | 1 % | 30 | GM | 52.98 | 601,164 | 0.03% | 0.03% | N | 1.77 | | |
| 22 | DICLOFENAC M2A2 | DUOFAM 15 GM GEL | DUOFAM GEL | MANEESH PHARMACEUTICALS LTD. | 1 % | 15 | GM | 35.56 | 3,420,907 | 0.16% | 0.41% | N | 2.37 | | |
| 23 | DICLOFENAC M2A2 | DUOFAM 30 GM GEL | DUOFAM GEL | MANEESH PHARMACEUTICALS LTD. | 1 % | 30 | GM | 59.11 | 5,489,132 | 0.25% | 0.41% | N | 1.97 | | |
| 24 | DICLOFENAC M2A2 | NOBEL10 GM GEL | NOBEL GEL | MANKIND | 1 % | 10 | GM | 17.05 | 33,600,000 | 1.54% | 4.75% | Y | 1.71 | 1.71 | |
| 25 | DICLOFENAC M2A2 | NOBEL 30 GM GEL | NOBEL GEL | MANKIND | 1 % | 30 | GM | 42.41 | 69,800,000 | 3.21% | 4.75% | Y | 1.41 | 1.41 | |
| 26 | DICLOFENAC M2A2 | DIVON 1 % GEL 10 GM | DIVON | MICRO LABS LTD | 1 % | 10 | GM | 24.27 | 10,603,165 | 0.49% | 1.40% | Y | 2.43 | 2.43 | |
| 27 | DICLOFENAC M2A2 | DIVON 1 % GEL 30 GM | DIVON | MICRO LABS LTD | 1 % | 30 | GM | 66.21 | 19,790,553 | 0.91% | 1.40% | Y | 2.21 | 2.21 | |
| 28 | DICLOFENAC M2A2 | VOVERAN EMULGEL 1 % GEL 21 GM | VOVERAN | NOVARTIS INDIA LTD | 1 % | 21 | GM | 53.26 | 62,360,616 | 2.87% | 8.45% | Y | 2.54 | 2.54 | |
| 29 | DICLOFENAC M2A2 | VOVERAN EMULGEL 1 % GEL 50 GM | VOVERAN | NOVARTIS INDIA LTD | 1 % | 50 | GM | 133.92 | 71,683,870 | 3.30% | 8.45% | Y | 2.68 | 2.68 | |
| 30 | DICLOFENAC M2A2 | VOVERAN TPM 1 % GEL 30 GM | VOVERAN | NOVARTIS INDIA LTD | 1 % | 30 | GM | 80.34 | 49,493,321 | 2.28% | 8.45% | Y | 2.68 | 2.68 | |
| 31 | DICLOFENAC M2A2 | MISONAC 1 % GEL 30 GM | MISONAC | ORDAIN HEALTHCARE PVT. LTD | 1 % | 30 | GM | 66.36 | 2,042,960 | 0.09% | 0.09% | N | 2.21 | | |
| 32 | DICLOFENAC M2A2 | DFO GEL 30GM | DFO | OZONE PHARMACEUTICALS LTD. | 1 % | 30 | GM | 60.81 | 152,805,528 | 7.03% | 7.59% | Y | 2.03 | 2.03 | |
| 33 | DICLOFENAC M2A2 | DFO GEL 30GM | DFO | OZONE PHARMACEUTICALS LTD. | 1 % | 30 | GM | 56.07 | 12,083,379 | 0.56% | 7.59% | Y | 1.87 | 1.87 | |
| 34 | DICLOFENAC M2A2 | DOLFRE 1 % GEL 30 GM | DOLFRE | RAVENBHEL PHARMACEUTICALS PVT LTD. | 1 % | 30 | GM | 56.07 | 1,379,730 | 0.06% | 0.06% | N | 1.87 | | |
| 35 | DICLOFENAC M2A2 | TRAUMANIL(RUI) 1 % GEL 30 GM | TRAUMANIL(RUI) | RUSI REMEDIES P. LTD. | 1 % | 30 | GM | 41.72 | 307,908 | 0.01% | 0.01% | N | 1.39 | | |
| 36 | DICLOFENAC M2A2 | VOLINI 30 GM GEL | VOLINI GEL | SUN PHARMA | 1 % | 30 | GM | 69.27 | 524,918,617 | 24.14% | 55.65% | Y | 2.31 | 2.31 | |
| 37 | DICLOFENAC M2A2 | VOLINI 15 GM GEL | VOLINI GEL | SUN PHARMA | 1 % | 15 | GM | 38.49 | 281,026,988 | 12.92% | 55.65% | Y | 2.57 | 2.57 | |
| 38 | DICLOFENAC M2A2 | VOLINI 50 GM GEL | VOLINI GEL | SUN PHARMA | 1 % | 50 | GM | 103.91 | 193,753,868 | 8.91% | 55.65% | Y | 2.08 | 2.08 | |
| 39 | DICLOFENAC M2A2 | VOLINI 75 GM GEL | VOLINI GEL | SUN PHARMA | 1 % | 75 | GM | 142.40 | 143,292,242 | 6.59% | 55.65% | Y | 1.90 | 1.90 | |
| 40 | DICLOFENAC M2A2 | VOLINI 10 GM GEL | VOLINI GEL | SUN PHARMA | 1 % | 10 | GM | 20.78 | 26,715,703 | 1.23% | 55.65% | Y | 2.08 | 2.08 | |
| 41 | DICLOFENAC M2A2 | VOLINI 100 GM GEL | VOLINI GEL | SUN PHARMA | 1 % | 100 | GM | 165.54 | 21,526,491 | 0.99% | 55.65% | Y | 1.66 | 1.66 | |
| 42 | DICLOFENAC M2A2 | VOLINI 5 GM GEL | VOLINI GEL | SUN PHARMA | 1 % | 5 | GM | 7.93 | 19,015,640 | 0.87% | 55.65% | Y | 1.59 | 1.59 | |
| 43 | DICLOFENAC M2A2 | SYSTAFLAM 1 % GEL 25 GM | SYSTAFLAM | SYSTOPIK LABORATORIES LTD-MEM | 1 % | 25 | GM | 50.03 | 39,529,078 | 1.82% | 2.68% | Y | 2.00 | 2.00 | |
| 44 | DICLOFENAC M2A2 | SYSTAFLAM 1 % GEL 50 GM | SYSTAFLAM | SYSTOPIK LABORATORIES LTD-MEM | 1 % | 50 | GM | 76.22 | 18,736,248 | 0.86% | 2.68% | Y | 1.52 | 1.52 | |
| 45 | DICLOFENAC M2A2 | DICLODYNE 1 % GEL 30 GM | DYNAPAR | TROIKKA PHARMACEUTICALS LTD. | 1 % | 30 | GM | 68.57 | 38,320,000 | 1.76% | 1.76% | Y | 2.29 | 2.29 | |
| 46 | DICLOFENAC M2A2 | DICLOWIN PLUS 1 % GEL 30 GM | DICLOWIN PLUS | WINGS PHARMACEUTICALS PVT. LTD. | 1 % | 30 | GM | 28.00 | 1,620,818 | 0.07% | 0.07% | N | 0.93 | | |
| 47 | DICLOFENAC M2A2 | DICLOMOL 1 % GEL 20 GM | DICLOMOL | WIN-MEDICARE PVT. LTD. | 1 % | 20 | GM | 62.10 | 332,122 | 0.02% | 0.02% | N | 3.11 | | |

| Computation of Ceiling Price based on Aug 2015 Data under Para 6 of DPCO 2013 | | | | | | | | | | | | |
|---|------------------------|-------------------------|-------------------------------|--|------------------------------|---|-----------|---------|--|-----------|---------|---------------------------------|
| | | | | | | | | | | | | |
| | | | | | | | | | | | 1 | |
| 12.1.3 | Diltiazem | Capsule 60 mg | Per Capsule | | | | | | Number of Companies consisting of Market Share of 1% & Above | | | |
| | | | | | | | | | Sum of MAT value considered for price calculation (in Lakhs) | | 0.02 | |
| | | | | | | | | | PTR under Consideration | | 5.11 | |
| | | | | | | | | | % Reduction with compared to Highest Price (average) | | 2.73% | |
| | | | | | | | | | Reduction as per Monopoly condition | | 0.14 | |
| | | | | | | | | | PTR after Reduction | | 4.97 | |
| | | | | | | | | | Add : 16% Retailer Margin | | 0.80 | |
| | | | | | | | | | Ceiling Price (without local taxes) (wef. 10.3.2016) | | 5.77 | |
| | | | | | | | | | WPI Reduction wef 1.4.2016 @ -2.7105% | | 0.16 | |
| | | | | | | | | | WPI Increase wef 01.4.2017 @ 1.97186% | | 0.11 | |
| | | | | | | | | | Final Ceiling Price (without local taxes) (wef. 01.4.2017 or date of notification, whichever is later) | | 5.72 | |
| A. List of Item Under consideration | | | | | | | | | | TOTAL MAT | 1,534 | |
| S. No. | Unique No. as per NLEM | Composition as per NLEM | पैक विवरण Pack Description | छाप BRAND | कंपनी Company | Strength | Pack Size | Unit | PTR (Rs.) | MAT (Rs.) | MAT (%) | Price per Unit Considered (Rs.) |
| 1 | 12.1.3 | DILTIAZEM C8A6 | ANGIZEM DP 60 MG CAPSULE 10 | ANGIZEM DP | SUN PHARMA LABORATORIES LTD. | 60 MG | 10 | CAPSULE | 51.12 | 1533.6 | 100.00% | 5.11 |
| B. Computation of Average rate of Reduction under Monopoly | | | | | | | | | | | | |
| S. No. | Drug(s) | Strength | Description | Route of Administration/ Dosage Form & packsize/packing, if any | S.O. number & date | Reduction with reference to the highest PTR under NLEM 2015 (%) | | | | | | |
| 1 | Diltiazem | SR Tablet 90 mg | DiltiazemSR Tablet 90 mg | Tablet | 1254(E) dated 29.3.2016 | 3.28 | | | | | | |
| 2 | Diltiazem | Tablet 30 mg | DiltiazemTablet 30 mg | Tablet | 2195(E) dated 23.6.2016 | 2.48 | | | | | | |
| 3 | Diltiazem | Tablet 60 mg | DiltiazemTablet 60 mg | Tablet | 2195(E) dated 23.6.2016 | 2.43 | | | | | | |
| 4 | Diltiazem | Injection 5 mg/ml | DiltiazemInjection 5 mg/ml | Injection | 4128(E) dated 22.12.2016 | 2.73 | | | | | | |
| Average Reduction | | | | | | 2.73 | | | | | | |

| Computation of Ceiling Price based on Aug 2015 Data under Para 6 of DPCO 2013 | | | | | | | | | | | | |
|---|------------------------|-------------------------|-------------------------------|--|--------------------------------|---|-----------|---------|-----------|-----------|--|---------------------------------|
| | | | | | | | | | | | 1 | |
| 2.1.2 | Diclofenac | Capsule 50 mg | Per Capsule | | | | | | | | | |
| | | | | | | | | | | | Number of Companies consisting of Market Share of 1% & Above | |
| | | | | | | | | | | | Sum of MAT value considered for price calculation (in Lakhs) | |
| | | | | | | | | | | | 0.05 | |
| | | | | | | | | | | | PTR under Consideration | |
| | | | | | | | | | | | 0.60 | |
| | | | | | | | | | | | % Reduction with compared to Highest Price (average) | |
| | | | | | | | | | | | 15.02% | |
| | | | | | | | | | | | Reduction as per Monopoly condition | |
| | | | | | | | | | | | 0.09 | |
| | | | | | | | | | | | PTR after Reduction | |
| | | | | | | | | | | | 0.51 | |
| | | | | | | | | | | | Add : 16% Retailer Margin | |
| | | | | | | | | | | | 0.08 | |
| | | | | | | | | | | | Ceiling Price (without local taxes) (wef. 10.3.2016) | |
| | | | | | | | | | | | 0.59 | |
| | | | | | | | | | | | WPI Reduction wef 1.4.2016 @ -2.7105% | |
| | | | | | | | | | | | 0.02 | |
| | | | | | | | | | | | WPI Increase wef 01.4.2017 @ 1.97186% | |
| | | | | | | | | | | | 0.01 | |
| | | | | | | | | | | | Final Ceiling Price (without local taxes) (wef. 01.4.2017 or date of notification, whichever is later) | |
| | | | | | | | | | | | 0.58 | |
| A. List of Item Under consideration | | | | | | | | | | TOTAL MAT | 4,720 | |
| S. No. | Unique No. as per NLEM | Composition as per NLEM | पैक विवरण Pack Description | छाप BRAND | कंपनी Company | Strength | Pack Size | Unit | PTR (Rs.) | MAT (Rs.) | MAT (%) | Price per Unit Considered (Rs.) |
| 1 | 2.1.2 | DICLOFENAC M1A12 | TROMAX 50 MG CAPSULE 10 | TROMAX | ARISTO PHARMACEUTICALS PVT.LTD | 50 MG | 10 | CAPSULE | 5.96 | 4720 | 100.00% | 0.60 |
| B. Computation of Average rate of Reduction under Monopoly | | | | | | | | | | | | |
| S. No. | Drug(s) | Strength | Description | Route of Administration/ Dosage Form & packsize/packing, if any | S.O. number & date | Reduction with reference to the highest PTR under NLEM 2015 (%) | | | | | | |
| 1 | Diclofenac | 50mg Tablet | Diclofenac50mg Tablet | Tablet | 1951(E) dated 2.6.2016 | 15.14 | | | | | | |
| 2 | Diclofenac | Injection 25 mg/ml | DiclofenacInjection 25 mg/ml | Injection | 4128(E) dated 22.12.2016 | 14.89 | | | | | | |
| Average Reduction | | | | | | 15.02 | | | | | | |

| डीपीसीओ 2013 के पैरा 4 के तहत, अगस्त 2015 के आंकड़ों के आधारित, मूल्य की संगणना | | | | | | | | | | | | | | |
|---|------------------------|-------------------------|-------------------------------|--------------|------------------|----------|-----------|--------|-----------|--|-------------------|-----------------------------------|-------------------------|------------------------------------|
| Computation of Ceiling Price based on Aug-2015 Data under Para 4 of DPCO 2013 | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | Number of Companies consisting of Market Share of 1% & Above | | | | 1 |
| 6.2.3.3 | Rifampicin | Tablet 150 mg | Per Tablet | | | | | | | Sum of MAT value considered for price calculation (in Lakhs) | | | | 0.53 |
| | | | | | | | | | | Sum of PTR per unit considered for price calculation | | | | 1.55 |
| | | | | | | | | | | Number of Packs considered | | | | 1 |
| | | | | | | | | | | Average PTR | | | | 1.55 |
| | | | | | | | | | | Add : 16% Retailer Margin | | | | 0.25 |
| | | | | | | | | | | Ceiling Price (without local taxes) (wef. 10.03.2016) | | | | 1.80 |
| | | | | | | | | | | % Reduction with compared to Highest Price | | | | 0.00% |
| | | | | | | | | | | WPI Reduction wef 1.4.2016 @ -2.7105% | | | | 0.05 |
| | | | | | | | | | | WPI Increase wef 01.4.2017 @ 1.97186% | | | | 0.03 |
| | | | | | | | | | | Final Ceiling Price (wef. 01.4.2017 or date of notification, whichever is later) | | | | 1.78 |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | S.O. 836(E) dated 15.6.2005 | | | | |
| | | | | | | | | | | Minimum Price (Rs.) | | | | 1.55 |
| | | | | | | | | | | Ceiling Price as per DPCO, 1995 | | | | 1.55 |
| | | | | | | | | | | 13.33/10's+6.18% ED+10% p.a. For 3 years | 1.88 | Per Tablet | | 1.55 |
| | | | | | | | | | | Average of all considered (Rs.) | | | | 1.55 |
| | | | | | | | | | | Derived Ceiling PTR | 1.62 | | | 1.80 |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | TOTAL MAT | 53,477 | 100% | | |
| S. No. | Unique No. as per NLEM | Composition as per NLEM | पैक विवरण Pack Description | छाप BRAND | कंपनी Company | Strength | Pack Size | Unit | PTR (Rs.) | MAT (Rs.) | SKU wise MAT % | Qualify (Y/N) Y=Yes N=No | Price per Unit (Rs.) | Price per Unit (Rs.) Considered |
| 1 | 6.2.3.3 | RIFAMPICIN J4A12 | R-CIN 150 MG TABLET 20 | R-CIN | LUPIN LTD | 150 MG | 20 | TABLET | 30.98 | 53477 | 100.00% | Y | 1.55 | 1.55 |